SCHEMBL24254489

SCHEMBL24254489

Cc1ccc(S(=O)(=O)Nc2ccc(N3CCN(C)CC3)cc2)cc1N

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
LMNA P02545 3/20 0.55
MAPT P10636 5/20 0.53
RECQL P46063 1/20 0.53
USP2 O75604 1/20 0.52
POLB P06746 1/20 0.52
RAD52 P43351 2/20 0.51
HTR1A P08908 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
HTR7 P34969 1/20 0.51
DRD3 P35462 1/20 0.51
HTR6 P50406 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
GFER P55789 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
PKM P14618 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23758920 0.79 LDLR (0.53) ALDH1A1LMNAPOLBRAD52HTR1A
SCHEMBL9761881 0.79 MAPT (0.50) ALDH1A1LMNAMAPTPOLBSMN1; SMN2
SCHEMBL22778807 0.77 LMNA (0.61) ALDH1A1LMNAMAPTRECQLPOLB
SCHEMBL17740376 0.77 HTR6 (0.65) ALDH1A1LMNAMAPTRECQLUSP2
SCHEMBL22778895 0.77 PGR (0.61) ALDH1A1LMNAMAPTRAD52HTR1A
SCHEMBL11070041 0.76 KMT2A (0.60) ALDH1A1LMNAMAPTPOLBHTR6
SCHEMBL29902399 0.75 ALDH1A1 (0.58) ALDH1A1LMNAMAPTRECQLUSP2
SCHEMBL1527203 0.75 GAA (0.64) ALDH1A1MAPTRECQLPOLBRAD52
SCHEMBL30900439 0.75 GAA (0.64) ALDH1A1MAPTRECQLPOLBRAD52
SCHEMBL24254524 0.75 CYP3A4 (0.61) ALDH1A1LMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885LMNA 3727/4885MAPT 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.